STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNGX
  4. [EFFECT] SOLIGENIX, INC. SEC Filing

[EFFECT] SOLIGENIX, INC. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: April 2, 2026
Accession Number: 0001104659-26-037730
Submission Type: POS AM
CIK: 0000812796
Company Name: SOLIGENIX, INC.
File Number: 333-280993

Source: View Original Filing on SEC EDGAR

Soligenix Inc

NASDAQ:SNGX

View SNGX Stock Overview →

SNGX Rankings

#6364 Ranked by Market Cap
N/A Ranked by Dividends

SNGX Latest News

Apr 2, 2026
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Mar 31, 2026
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Mar 26, 2026
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
Mar 23, 2026
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
Mar 19, 2026
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

SNGX Latest SEC Filings

Apr 3, 2026
[EFFECT] SOLIGENIX, INC. SEC Filing
Mar 31, 2026
[POS AM] SOLIGENIX, INC. SEC Filing
Mar 31, 2026
[POS AM] SOLIGENIX, INC. SEC Filing
Mar 31, 2026
[POS AM] SOLIGENIX, INC. SEC Filing
Mar 31, 2026
[POS AM] SOLIGENIX, INC. SEC Filing

SNGX Stock Data

11.60M
9.65M
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON